Rein Therapeutics Inc. (RNTX)
Oxford Ledge is still expanding full research coverage of RNTX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A clinical stage biotech company developing LTI-03, a peptide therapy for idiopathic pulmonary fibrosis, after pausing other programs due to insufficient funding.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-08
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-05-04
- S-1 IPO / securities registration statement 2026-04-28
- 10-K/A Amended annual report 2026-04-27
Source: SEC EDGAR.
Annual results
5 years of annual figures for RNTX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $0 | -$49.9M | -$1.96 |
| 2024 | $0 | -$62.9M | -$3.51 |
| 2023 | $0 | -$15.7M | -$3.42 |
| 2022 | $0 | -$27.3M | -$6.02 |
| 2021 | $0 | -$26.2M | -$5.89 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for RNTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open RNTX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.